Clinical Trial

New data on elecoglipron, an oral pill with no food restrictions, shows major weight loss and A1C reduction, positioning AstraZeneca to disrupt the GLP-1 market.

New data on Eli Lilly's oral GLP-1, orforglipron, shows superior results over rivals, promising a new era for millions of needle-averse patients.

An aging world and failing antibiotics are driving a surge in pneumonia. Now, a new generation of therapies is being built to fight back. Here's how.

A landmark drug approval in China offers new hope for IgAN patients. But the real story is how science, strategy, and policy are converging to build a better future.

Septerna's novel oral drug for hypoparathyroidism could end the tyranny of injections and supplements, but its success hinges on a bigger bet: a new system for drugging life's most difficult molecular targets.

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.

New trial data shows Sequel Med Tech's twiist™ AID system could bring much-needed simplicity and safety to millions with insulin-treated type 2 diabetes.

Mineralys Therapeutics' Lorundrostat shows promise in reducing heart failure risk, a breakthrough for millions struggling with uncontrolled hypertension.

Amai Proteins' sweelin® just got a major scientific boost. New clinical data in a top journal proves its metabolic safety, fast-tracking its commercial journey.

Hong Kong's NatureU touts impressive anti-aging results on a public registry, but a closer look reveals a complex strategy blending early science with savvy marketing.

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

Market research shows doctors are eager to prescribe Moleculin's new AML drug, Annamycin. It offers hope where there is none, but can the company survive to deliver it?

BioCardia’s innovative cell therapy for heart failure receives a crucial FDA signal, potentially paving the way for a new treatment paradigm for millions.

Landmark trial results for Bayer's KERENDIA unlock a vast new market in non-diabetic kidney disease, offering hope to millions and a strategic win for the firm.

A private startup just achieved a nuclear first in 40 years. This rapid milestone, driven by new policy, signals a new era for energy innovation.

Swedish innovator Triomed AB unveils a system that triples ultrafiltration in peritoneal dialysis, tackling a critical patient risk and challenging market leaders.

Pivotal data on zilurgisertib offers hope for FOP patients, as Mirum and Incyte navigate a fast-track FDA review for this groundbreaking ALK2 inhibitor.

With an FDA decision just weeks away, Ionis's olezarsen could redefine care for a debilitating condition, marking a pivotal moment for RNA-targeted medicine.

Syndax Pharmaceuticals secures a $250M war chest via convertible notes. We decode the deal, what it means for its cancer drugs, and why it's a savvy move.